Design and synthesis of Rho kinase inhibitors (I)

Structure-based design of several scaffolds of Rho kinase inhibitor was performed by using pharmacophore information obtained from a high-throughput screening and the enzyme homology model. Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore informa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry 2004-05, Vol.12 (9), p.2115-2137
Hauptverfasser: Takami, Atsuya, Iwakubo, Masayuki, Okada, Yuji, Kawata, Takehisa, Odai, Hideharu, Takahashi, Nobuaki, Shindo, Kazutoshi, Kimura, Kaname, Tagami, Yoshimichi, Miyake, Mika, Fukushima, Kayoko, Inagaki, Masaki, Amano, Mutsuki, Kaibuchi, Kozo, Iijima, Hiroshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2137
container_issue 9
container_start_page 2115
container_title Bioorganic & medicinal chemistry
container_volume 12
creator Takami, Atsuya
Iwakubo, Masayuki
Okada, Yuji
Kawata, Takehisa
Odai, Hideharu
Takahashi, Nobuaki
Shindo, Kazutoshi
Kimura, Kaname
Tagami, Yoshimichi
Miyake, Mika
Fukushima, Kayoko
Inagaki, Masaki
Amano, Mutsuki
Kaibuchi, Kozo
Iijima, Hiroshi
description Structure-based design of several scaffolds of Rho kinase inhibitor was performed by using pharmacophore information obtained from a high-throughput screening and the enzyme homology model. Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure–activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1 H-indazole, isoquinoline, and phthalimide.
doi_str_mv 10.1016/j.bmc.2004.02.025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71828945</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089604001476</els_id><sourcerecordid>71828945</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-8f106bd7c03dd8c310d237ec876bf826da36bbda242910c630a7354cf2488bb93</originalsourceid><addsrcrecordid>eNp9kMtKw0AUhgdRbK0-gBvJRtFF4pmZZDLBldRboSCIroe5xU7Npc6kQt_e1AZ0JRw4HPj-n8OH0CmGBANm18tE1TohAGkCpJ9sD41xytKY0gLvozEUjMfACzZCRyEsAYCkBT5EI5wBhwLTMcJ3Nrj3JpKNicKm6Rb9GaK2jF4WbfThGhls5JqFU65rfYguZ1fH6KCUVbAnw56gt4f71-lTPH9-nE1v57GmHHcxLzEwZXIN1BiuKQZDaG41z5kqOWFGUqaUkSQlBQbNKMicZqkuScq5UgWdoItd78q3n2sbOlG7oG1Vyca26yByzAkv0qwH8Q7Uvg3B21KsvKul3wgMYutJLEXvSWw9CSD9bDNnQ_la1db8JgYxPXA-ADJoWZVeNtqFPxzjNPvhbnac7VV8OetF0M422hrnre6Ead0_b3wDNqqDCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71828945</pqid></control><display><type>article</type><title>Design and synthesis of Rho kinase inhibitors (I)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Takami, Atsuya ; Iwakubo, Masayuki ; Okada, Yuji ; Kawata, Takehisa ; Odai, Hideharu ; Takahashi, Nobuaki ; Shindo, Kazutoshi ; Kimura, Kaname ; Tagami, Yoshimichi ; Miyake, Mika ; Fukushima, Kayoko ; Inagaki, Masaki ; Amano, Mutsuki ; Kaibuchi, Kozo ; Iijima, Hiroshi</creator><creatorcontrib>Takami, Atsuya ; Iwakubo, Masayuki ; Okada, Yuji ; Kawata, Takehisa ; Odai, Hideharu ; Takahashi, Nobuaki ; Shindo, Kazutoshi ; Kimura, Kaname ; Tagami, Yoshimichi ; Miyake, Mika ; Fukushima, Kayoko ; Inagaki, Masaki ; Amano, Mutsuki ; Kaibuchi, Kozo ; Iijima, Hiroshi</creatorcontrib><description>Structure-based design of several scaffolds of Rho kinase inhibitor was performed by using pharmacophore information obtained from a high-throughput screening and the enzyme homology model. Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure–activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1 H-indazole, isoquinoline, and phthalimide.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2004.02.025</identifier><identifier>PMID: 15080913</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Amino Acid Sequence ; Biological and medical sciences ; Enzyme Inhibitors - chemical synthesis ; Enzyme Inhibitors - chemistry ; Enzyme Inhibitors - pharmacology ; Inhibitor ; Intracellular Signaling Peptides and Proteins ; Ligands ; Magnetic Resonance Spectroscopy ; Medical sciences ; Miscellaneous ; Models, Molecular ; Molecular Sequence Data ; Pharmacology. Drug treatments ; Protein-Serine-Threonine Kinases - antagonists &amp; inhibitors ; Rho kinase ; rho-Associated Kinases ; Sequence Homology, Amino Acid ; Spectrometry, Mass, Electrospray Ionization ; Structure-based drug design ; Structure–activity relationship</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2004-05, Vol.12 (9), p.2115-2137</ispartof><rights>2004 Elsevier Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-8f106bd7c03dd8c310d237ec876bf826da36bbda242910c630a7354cf2488bb93</citedby><cites>FETCH-LOGICAL-c381t-8f106bd7c03dd8c310d237ec876bf826da36bbda242910c630a7354cf2488bb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0968089604001476$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15683513$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15080913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takami, Atsuya</creatorcontrib><creatorcontrib>Iwakubo, Masayuki</creatorcontrib><creatorcontrib>Okada, Yuji</creatorcontrib><creatorcontrib>Kawata, Takehisa</creatorcontrib><creatorcontrib>Odai, Hideharu</creatorcontrib><creatorcontrib>Takahashi, Nobuaki</creatorcontrib><creatorcontrib>Shindo, Kazutoshi</creatorcontrib><creatorcontrib>Kimura, Kaname</creatorcontrib><creatorcontrib>Tagami, Yoshimichi</creatorcontrib><creatorcontrib>Miyake, Mika</creatorcontrib><creatorcontrib>Fukushima, Kayoko</creatorcontrib><creatorcontrib>Inagaki, Masaki</creatorcontrib><creatorcontrib>Amano, Mutsuki</creatorcontrib><creatorcontrib>Kaibuchi, Kozo</creatorcontrib><creatorcontrib>Iijima, Hiroshi</creatorcontrib><title>Design and synthesis of Rho kinase inhibitors (I)</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>Structure-based design of several scaffolds of Rho kinase inhibitor was performed by using pharmacophore information obtained from a high-throughput screening and the enzyme homology model. Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure–activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1 H-indazole, isoquinoline, and phthalimide.</description><subject>Amino Acid Sequence</subject><subject>Biological and medical sciences</subject><subject>Enzyme Inhibitors - chemical synthesis</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Inhibitor</subject><subject>Intracellular Signaling Peptides and Proteins</subject><subject>Ligands</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Models, Molecular</subject><subject>Molecular Sequence Data</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein-Serine-Threonine Kinases - antagonists &amp; inhibitors</subject><subject>Rho kinase</subject><subject>rho-Associated Kinases</subject><subject>Sequence Homology, Amino Acid</subject><subject>Spectrometry, Mass, Electrospray Ionization</subject><subject>Structure-based drug design</subject><subject>Structure–activity relationship</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKw0AUhgdRbK0-gBvJRtFF4pmZZDLBldRboSCIroe5xU7Npc6kQt_e1AZ0JRw4HPj-n8OH0CmGBANm18tE1TohAGkCpJ9sD41xytKY0gLvozEUjMfACzZCRyEsAYCkBT5EI5wBhwLTMcJ3Nrj3JpKNicKm6Rb9GaK2jF4WbfThGhls5JqFU65rfYguZ1fH6KCUVbAnw56gt4f71-lTPH9-nE1v57GmHHcxLzEwZXIN1BiuKQZDaG41z5kqOWFGUqaUkSQlBQbNKMicZqkuScq5UgWdoItd78q3n2sbOlG7oG1Vyca26yByzAkv0qwH8Q7Uvg3B21KsvKul3wgMYutJLEXvSWw9CSD9bDNnQ_la1db8JgYxPXA-ADJoWZVeNtqFPxzjNPvhbnac7VV8OetF0M422hrnre6Ead0_b3wDNqqDCA</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Takami, Atsuya</creator><creator>Iwakubo, Masayuki</creator><creator>Okada, Yuji</creator><creator>Kawata, Takehisa</creator><creator>Odai, Hideharu</creator><creator>Takahashi, Nobuaki</creator><creator>Shindo, Kazutoshi</creator><creator>Kimura, Kaname</creator><creator>Tagami, Yoshimichi</creator><creator>Miyake, Mika</creator><creator>Fukushima, Kayoko</creator><creator>Inagaki, Masaki</creator><creator>Amano, Mutsuki</creator><creator>Kaibuchi, Kozo</creator><creator>Iijima, Hiroshi</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Design and synthesis of Rho kinase inhibitors (I)</title><author>Takami, Atsuya ; Iwakubo, Masayuki ; Okada, Yuji ; Kawata, Takehisa ; Odai, Hideharu ; Takahashi, Nobuaki ; Shindo, Kazutoshi ; Kimura, Kaname ; Tagami, Yoshimichi ; Miyake, Mika ; Fukushima, Kayoko ; Inagaki, Masaki ; Amano, Mutsuki ; Kaibuchi, Kozo ; Iijima, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-8f106bd7c03dd8c310d237ec876bf826da36bbda242910c630a7354cf2488bb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Amino Acid Sequence</topic><topic>Biological and medical sciences</topic><topic>Enzyme Inhibitors - chemical synthesis</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Inhibitor</topic><topic>Intracellular Signaling Peptides and Proteins</topic><topic>Ligands</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Models, Molecular</topic><topic>Molecular Sequence Data</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein-Serine-Threonine Kinases - antagonists &amp; inhibitors</topic><topic>Rho kinase</topic><topic>rho-Associated Kinases</topic><topic>Sequence Homology, Amino Acid</topic><topic>Spectrometry, Mass, Electrospray Ionization</topic><topic>Structure-based drug design</topic><topic>Structure–activity relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takami, Atsuya</creatorcontrib><creatorcontrib>Iwakubo, Masayuki</creatorcontrib><creatorcontrib>Okada, Yuji</creatorcontrib><creatorcontrib>Kawata, Takehisa</creatorcontrib><creatorcontrib>Odai, Hideharu</creatorcontrib><creatorcontrib>Takahashi, Nobuaki</creatorcontrib><creatorcontrib>Shindo, Kazutoshi</creatorcontrib><creatorcontrib>Kimura, Kaname</creatorcontrib><creatorcontrib>Tagami, Yoshimichi</creatorcontrib><creatorcontrib>Miyake, Mika</creatorcontrib><creatorcontrib>Fukushima, Kayoko</creatorcontrib><creatorcontrib>Inagaki, Masaki</creatorcontrib><creatorcontrib>Amano, Mutsuki</creatorcontrib><creatorcontrib>Kaibuchi, Kozo</creatorcontrib><creatorcontrib>Iijima, Hiroshi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takami, Atsuya</au><au>Iwakubo, Masayuki</au><au>Okada, Yuji</au><au>Kawata, Takehisa</au><au>Odai, Hideharu</au><au>Takahashi, Nobuaki</au><au>Shindo, Kazutoshi</au><au>Kimura, Kaname</au><au>Tagami, Yoshimichi</au><au>Miyake, Mika</au><au>Fukushima, Kayoko</au><au>Inagaki, Masaki</au><au>Amano, Mutsuki</au><au>Kaibuchi, Kozo</au><au>Iijima, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design and synthesis of Rho kinase inhibitors (I)</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>12</volume><issue>9</issue><spage>2115</spage><epage>2137</epage><pages>2115-2137</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>Structure-based design of several scaffolds of Rho kinase inhibitor was performed by using pharmacophore information obtained from a high-throughput screening and the enzyme homology model. Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure–activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1 H-indazole, isoquinoline, and phthalimide.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15080913</pmid><doi>10.1016/j.bmc.2004.02.025</doi><tpages>23</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2004-05, Vol.12 (9), p.2115-2137
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_71828945
source MEDLINE; Elsevier ScienceDirect Journals
subjects Amino Acid Sequence
Biological and medical sciences
Enzyme Inhibitors - chemical synthesis
Enzyme Inhibitors - chemistry
Enzyme Inhibitors - pharmacology
Inhibitor
Intracellular Signaling Peptides and Proteins
Ligands
Magnetic Resonance Spectroscopy
Medical sciences
Miscellaneous
Models, Molecular
Molecular Sequence Data
Pharmacology. Drug treatments
Protein-Serine-Threonine Kinases - antagonists & inhibitors
Rho kinase
rho-Associated Kinases
Sequence Homology, Amino Acid
Spectrometry, Mass, Electrospray Ionization
Structure-based drug design
Structure–activity relationship
title Design and synthesis of Rho kinase inhibitors (I)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T11%3A20%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20and%20synthesis%20of%20Rho%20kinase%20inhibitors%20(I)&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Takami,%20Atsuya&rft.date=2004-05-01&rft.volume=12&rft.issue=9&rft.spage=2115&rft.epage=2137&rft.pages=2115-2137&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2004.02.025&rft_dat=%3Cproquest_cross%3E71828945%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71828945&rft_id=info:pmid/15080913&rft_els_id=S0968089604001476&rfr_iscdi=true